Last10K.com

Aeglea Biotherapeutics, Inc. (AGLE) SEC Filing 8-K Material Event for the period ending Wednesday, February 9, 2022

Aeglea Biotherapeutics, Inc.

CIK: 1636282 Ticker: AGLE

View differences made from one to another to evaluate Aeglea Biotherapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aeglea Biotherapeutics, Inc..

Continue

Assess how Aeglea Biotherapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aeglea Biotherapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: AGLE
CIK: 1636282
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-032683
Submitted to the SEC: Wed Feb 09 2022 4:10:55 PM EST
Accepted by the SEC: Wed Feb 09 2022
Period: Wednesday, February 9, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Earnings Release

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/agle/0001193125-22-032683.htm